Literature DB >> 19620842

Triple negative breast carcinomas: similarities and differences with basal like carcinomas.

Enrique Lerma1, Agusti Barnadas, Jaime Prat.   

Abstract

The cDNA microarrays allows the classification of breast cancers into 6 groups: luminal A, luminal B, luminal C, normal breast-like, human epidermal growth factor receptor 2-positive, and basal-like. This latter is characterized by the expression of basal cytokeratins (CKs), and frequent negativity for hormone receptors and human epidermal growth factor receptor 2. There is a marked parallelism between triple negative breast carcinomas and basal-like carcinoma, but these are not equivalent terms. Estimated concordance is around 80%. CK5 seems to be the best marker for the identification of these tumors. Other good markers to identify these tumors are CK14, CK17, and epidermal growth factor receptor. A subset of triple negative breast carcinomas has myoepithelial differentiation, with positivities for smooth muscle actin, p63, S-100, and CD10 among others. Recent studies suggest that basal like carcinomas are originated from mammary stem cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620842     DOI: 10.1097/PAI.0b013e3181a725eb

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Ultrasonographic findings of triple-negative breast cancer.

Authors:  Hai-Yan Du; Bao-Rong Lin; Du-Ping Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Molecular morphological approach to the pathological study of development and advancement of human breast cancer.

Authors:  Takuya Moriya; Naoki Kanomata; Yuji Kozuka; Hisashi Hirakawa; Izo Kimijima; Michio Kimura; Mika Watanabe; Hironobu Sasano; Takanori Ishida; Noriaki Ohuchi; Jun-Ichi Kurebayashi; Hiroshi Sonoo
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

3.  Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.

Authors:  Annika N Alexopoulou; Maria Leao; Otavia L Caballero; Leonard Da Silva; Lynne Reid; Sunil R Lakhani; Andrew J Simpson; John F Marshall; A Munro Neville; Parmjit S Jat
Journal:  Breast Cancer Res       Date:  2010-07-19       Impact factor: 6.466

4.  Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

Authors:  Xiu Nie; Jun He; Yan Li; Dan-Zhen Pan; Hua-Xiong Pan; Mi-Xia Weng; Xiu-Ping Yang; Chun-Ping Liu; Tao Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

5.  Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.

Authors:  Natsumi Hasegawa; Akiko Sumitomo; Azusa Fujita; Nami Aritome; Shumpei Mizuta; Keiji Matsui; Ruri Ishino; Kana Inoue; Norinaga Urahama; Junko Nose; Toru Mukohara; Shingo Kamoshida; Robert G Roeder; Mitsuhiro Ito
Journal:  Mol Cell Biol       Date:  2012-02-13       Impact factor: 4.272

6.  BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.

Authors:  Abhilasha Sinha; Bibbin T Paul; Lisa M Sullivan; Hillary Sims; Ahmed El Bastawisy; Hend F Yousef; Abdel-Rahman N Zekri; Abeer A Bahnassy; Wael M ElShamy
Journal:  Oncotarget       Date:  2017-02-07

Review 7.  RAS as Supporting Actor in Breast Cancer.

Authors:  Mirco Galiè
Journal:  Front Oncol       Date:  2019-11-12       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.